Table 1. Patient characteristics.
| Number of patients | Total | November 1995 to July 2005 | August 2005 to April 2017 | P-value |
|---|---|---|---|---|
| 49 | 16 | 33 | ||
| Age, median (IQR) in years | 65 (59–70) | 66.5 (56.5–74.8) | 64 (59–69.5) | 0.4 |
| Sex, male/female | 29/20 | 10/6 | 19/14 | >0.99 |
| Tumor size, median (IQR) in mm | 11 (10–20) |
13 (10–25) |
11 (9–20) |
0.31 |
| Final histological diagnosis, n, (%) | 0.08 | |||
| Adenoma | 33 (67.3%) | 8 (50%) | 25 (75.8%) | |
| Carcinoma-in-adenoma | 6 (12.2%) | 4 (25%) | 2 (6.1%) | |
| Adenocarcinoma | 8 (16.3%) | 3 (18.8%) | 5 (15.2%) | |
| Hyperplasia | 1 (2%) | 0 | 1 (3.0%) | |
| No tumor | 1 (2%) | 1 (6.3%) | 0 | |
| En bloc resection | 41 (83.7%) | 12 (75%) | 29 (87.9%) | 0.41 |
| Additional therapy | 10 (20.4%) | 5 (31.3%) | 5 (15.2%) | 0.26 |
| Papillectomy/APC | 7 (14.3%) | 4 (25%) | 3 (9.1%) | 0.20 |
| Pancreatoduodenectomy | 3 (6.1%) | 1 (6.3%) | 2 (6.1%) | >0.99 |
| Adverse events | 17 (34.7%) | 7 (43.8%) | 10¶ (30.3%) | 0.52 |
| Pancreatitis | 4 (8.2%) | 2 (12.5%) | 2 (6.1%) | 0.59 |
| Bleeding | 10 (20.4%) | 4 (25%) | 6 (18.2%) | 0.71 |
| Cholangitis | 3 (6.1%) | 1 (6.3%) | 2 (6.1%) | >0.99 |
| Peritonitis | 1 (2.0%) | 0 | 1 (3.0%) | >0.99 |
¶One patient developed cholangitis and bleeding simultaneously.
IQR, interquartile range, APC, argon plasma coagulation